Ibrutinib Monotherapy Versus Fixed-duration Venetoclax Plus Obinutuzumab Versus Fixed-duration Ibrutinib Plus Venetoclax in Patients With Previously Untreated Chronic Lymphocytic Leukaemia (CLL)

NCT04608318 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

897

Enrollment

OTHER

Sponsor class

Conditions

Chronic Lymphoid Leukemia

Interventions

BIOLOGICAL: Ibrutinib
BIOLOGICAL: Venetoclax
BIOLOGICAL: Obinutuzumab

Sponsor

German CLL Study Group

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]